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HOFFMANN·LA ROCHE INC.
NUTl.EY e NEW JERSEY 07110 • TELEPHONE 1201) 23l5·l5000 • (N.Y.C.l 69l5·1400
ROCHE RESEARCH CENTER

January 4 ; 1988

Dear Dr.
Several of .us who are responsible for in:iustrial toxicology laboratories
met sane time ago to review our activities for the use of alt;e.n,atives to
animals for toxicity testi.n; an:l research. One of the out.cares of this
rreetirq was a resolve to see that those alteJ::natives which had reached a
practical level of use with orqoin; beneficial experience should be widely·
?,lblicized so that our peers could take advantage of this experience.
'Ihis letter is an invitation to share in the dissemination of this impor
tant activity within our laboratories. We will contact you by :,;hone in
the near future to confinn yoor potential irp.rt to the process. Research
studies on the topic are of interest, b.1t there are ample opportunities to
?,lblish· such procedures. We will be interested in those procedures that
have becale part of your current practice with identifiable benefits rela
tive to alteJ::natives.
We also invite your direct response to this prcp::,sal with constructive
criticism for its in1;,lementation. Several options have been discussed for
the dissemination process, b.1t we will await your input _before de:::isions
are made.
A second o.ito:rne of our earlier meet.in; was an awareness of. the value of
dialogue with. regulatory agencies.
eur personal goal of reduction, re
finement an:l replacement will oot be achieved in�that carp::,nent of our
work subject to regulatory review if there are agency barriers to these
alteJ::natives. Initial infarmal contacts have resulted in a favorable reac
tion for an exchan;e of ideas. We would consider sett.in; it up in the
Washin;ton area an:l inviting members of the regulatory agencies to atterx:i.
We will keep you informed as plans develop.
Sirx:erely yours,

t�6f-+

E. A. Pfitzer
Hoffmann-La Roche Inc.
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